These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12382520)

  • 21. Long-term outcome of low-grade oligodendroglioma and mixed glioma.
    Olson JD; Riedel E; DeAngelis LM
    Neurology; 2000 Apr; 54(7):1442-8. PubMed ID: 10751254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
    Sonabend AM; Lesniak MS
    Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of oligodendroglioma: an update.
    Paleologos NA; Cairncross JG
    Neuro Oncol; 1999 Jan; 1(1):61-8. PubMed ID: 11550303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term results of treatment in patients with oligodendrogliomas and oligoastrocytomas of the cerebral hemispheres].
    Iun'pén V; Oliushin VE; Ulitin AIu; Maslova LN; Petrov AA
    Zh Vopr Neirokhir Im N N Burdenko; 2008; (2):6-10; discussion 10-1. PubMed ID: 18720725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas.
    Kreiger PA; Okada Y; Simon S; Rorke LB; Louis DN; Golden JA
    Acta Neuropathol; 2005 Apr; 109(4):387-92. PubMed ID: 15739101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation.
    Koeller KK; Rushing EJ
    Radiographics; 2005; 25(6):1669-88. PubMed ID: 16284142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Histological and molecular classification of gliomas].
    Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
    Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiles associated with treatment response in oligodendrogliomas.
    French PJ; Swagemakers SM; Nagel JH; Kouwenhoven MC; Brouwer E; van der Spek P; Luider TM; Kros JM; van den Bent MJ; Sillevis Smitt PA
    Cancer Res; 2005 Dec; 65(24):11335-44. PubMed ID: 16357140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
    Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
    Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and management of oligodendroglioma.
    van den Bent MJ
    Semin Oncol; 2004 Oct; 31(5):645-52. PubMed ID: 15497117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
    Gadji M; Fortin D; Tsanaclis AM; Drouin R
    Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H
    Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
    Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Identification of genetic alterations by multiple ligation-dependent probe amplification (MLPA) analysis in oligodendrogliomas].
    Franco-Hernández C; Martínez-Glez V; Torres-Martín M; de Campos JM; Isla A; Vaquero J; Casartelli C; Rey JA
    Neurocirugia (Astur); 2009 Apr; 20(2):117-23. PubMed ID: 19448956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
    Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
    Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current diagnosis and treatment of oligodendroglioma.
    Engelhard HH
    Neurosurg Focus; 2002 Feb; 12(2):E2. PubMed ID: 16212319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
    Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
    Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligodendroglioma: does deferring treatment compromise outcome?
    Feigenberg SJ; Amdur RJ; Morris CG; Mendenhall WM; Marcus RB; Friedman WA
    Am J Clin Oncol; 2003 Jun; 26(3):e60-6. PubMed ID: 12796617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
    van den Bent MJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 19):39-44. PubMed ID: 14765384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.